J Korean Med Assoc.  2007 Aug;50(8):731-735. 10.5124/jkma.2007.50.8.731.

Treatment of Exudative Age-Related Macular Degeneration

• Jo NC

• KMID: 2184901
• DOI: http://doi.org/10.5124/jkma.2007.50.8.731

Abstract

Age-related macular degeneration (ARMD) is characterized by both primary and secondary damage of macular retinal pigment epithelial cell, resulting in the formation of drusen, choroidal neovascularization, and atrophy of photoreceptors and choriocapillaris layer of the choroid. After ARMD becomes exudative, laser photocoagulation, transpupillary thermotherapy, photodynamic therapy, intravitreal steroid injection, intravitreal anti-vascular endothelial growth factor injection, and surgical intervention are treatments to control choroidal neovascularization. In photodynamic therapy, a light-sensitive drug is administered by intravenous infusion and activated by a low-powered laser. Activated photosensitizer induces occlusion of the pathologic vasculature. Pegatanib, ranibizumab, and bevacizumab are anti-angiogenic agents, inhibiting the formation of neovascular membranes to prevent further development of the condition and to improve vision. This is thought to be due to the inhibition of vascular endothelial growth factor.

Keyword

Age-related macular degeneration; Photodynamic therapy; Anti-vascular endothelial growth factor

MeSH Terms

Atrophy
Bevacizumab
Choroid
Choroidal Neovascularization
Endothelial Growth Factors
Epithelial Cells
Hyperthermia, Induced
Infusions, Intravenous
Intravitreal Injections
Light Coagulation
Macular Degeneration*
Membranes
Photochemotherapy
Ranibizumab
Retinaldehyde
Vascular Endothelial Growth Factor A
Endothelial Growth Factors
Retinaldehyde
Vascular Endothelial Growth Factor A

Reference

1. Treatment of age related macular degeneration with photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999. 117:1329–1345.

2. Kim JW, Kim HK, Kim HC. Photodynamic therapy of choroidal neovascularization in age-related macular degeneration. J Korean Ophthalmol Soc. 2002. 43:1435–1443.

3. Verteporfin roundtable 2000 and 2001 participants: VIP & TAP study group principal investigators. Guidelines for using Verteporfin in photodynamic therapy to treat choroidal neovascularization due to age related macular degeneration and other causes. Retina. 2002. 22:6–18.

4. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol. 2001. 119:198–207.

5. Verteporfin in Photodynamic Therapy Study Group (VIP). Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a rando-mized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001. 131:541–560.

6. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Additional information regarding baseline lesion composition's impact on visual outcomes-TAP Report 3. Arch Ophthalmol. 2002. 120:1443–1454.

7. Rosenfeld PJ. Treatment of age-related macular degeneraiton with photodynamic therapy (TAP) study group. Visual outcomes in patients with minimally classic choroidal neovascularization (CNV): rationale for the Visudyne in minimally classic CNV(VIM) Trial [abstract]. Invest ophthalmol Vis Sci. 2001. 42:S512.

8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006. 355:1419–1431.

9. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006. 355:1432–1444.

10. Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006. 113:1508.